72
Participants
Start Date
September 14, 2020
Primary Completion Date
April 30, 2032
Study Completion Date
April 30, 2032
Nivolumab or Pembrolizumab (dependent upon approved indication)
Anti-PD-1 mAb (monoclonal antibody)
Metformin
Acts directly or indirectly on the liver to lower glucose production, and acts on the gut to increase glucose utilisation, increase GLP-1 and alter the microbiome.
Rosiglitazone
A member of the thiazolidinedione class of antidiabetic agents, improves glycemic control by improving insulin sensitivity. Rosiglitazone is a highly selective and potent agonist for the peroxisome proliferator-activated receptor-gamma (PPARγ).
RECRUITING
UPMC Hillman Cancer Center, Pittsburgh
Dan Zandberg
OTHER